Latest news

• Lundbeck challenge to EC pay-for-delay ruling fails

  Lundbeck was unable justify why the agreements were needed to protect its intellectual property rights on Celexa, according to the Commission. ... Lundbeck insists it did not go beyond the protection already offered by its patent rights on Celexa.

• Lundbeck and Otsuka's Rexulti set for August launch in US

  which it hopes will restore growth after the loss of patent protection on US blockbuster antidepressant Lexapro/Celexa (escitalopram).

• Lundbeck CEO resigns after rule breach

  Compounding this has been a legal battle with the European Commission, which ruled that Lundbeck collaborated with several other companies to delay the entry of generic competition for Celexa/ Cipramil (citalopram).

• EC fines J&J and Novartis in pay-for-delay case

  A case involving AstraZeneca and Nycomed was dropped last year. Earlier this year Danish pharma company Lundbeck was fined almost 94m for a pay-for-delay deal involving its antidepressant

• Lundbeck presses on with cost-saving programme

  its big-selling antidepressant Celexa/ Cipramil (citalopram).